Related Experiment Video
Updated: Mar 17, 2026

Vessel-sparing Excision and Primary Anastomosis
Published on: January 7, 2019
The Effect of Antiplatelet Agents on Bleeding-Related Complications After Ureteroscopy
Mary E Westerman1, Vidit Sharma1, Joseph Scales1
11 Department of Urology, Mayo Clinic , Rochester, Minnesota.
Insights
Continuing antiplatelet therapy (APT) during routine ureteroscopy (URS) is safe. This study found no increased risk of bleeding complications for patients who continued APT, supporting current AUA guidelines.
Area of Science:
- Urology
- Cardiovascular Medicine
- Surgical Complications
Background:
- Current American Urological Association (AUA) guidelines suggest continuing anticoagulation and antiplatelet therapy (APT) during routine ureteroscopy (URS) is safe.
- These guidelines are based on limited evidence from small case series.
- There is a need to further analyze bleeding risks associated with APT in URS procedures.
Purpose of the Study:
- To analyze bleeding-related complications in patients undergoing ureteroscopy (URS) while on antiplatelet therapy (APT).
- To evaluate the safety of continuing APT during routine URS procedures.
Main Methods:
- Retrospective review of 4799 URS procedures performed between June 2009 and February 2016.
- Identification of patients on APT (aspirin, P2Y12 inhibitors) and assessment of periprocedural complications.
- Exclusion of patients on concurrent anticoagulants or those undergoing additional non-URS procedures.
Main Results:
- Out of 4799 URS procedures, 314 (6.5%) involved patients on APT.
- The overall bleeding-related complication rate was 1.9%, with a significant bleeding rate of 1.6%.
- No significant difference in bleeding complications was observed between patients who continued APT and those who held it.
Conclusions:
- Continuing antiplatelet therapy (APT) in patients undergoing routine ureteroscopy (URS) does not appear to increase bleeding-related complications.
- These findings support the existing American Urological Association (AUA) guidelines regarding APT management during URS.
- The study provides evidence for the safety of continuing APT in this patient population.
Introduction:
The American Urological Association (AUA) guidelines state that continuing anticoagulation and antiplatelet agents in routine ureteroscopy (URS) is safe and without increased risk of complications. However, these recommendations are based on small case series; thus, we sought to analyze bleeding-related complications among patients on antiplatelet therapy (APT).
Materials And Methods:
Overall, 4799 URS procedures performed at our institution between June 2009 and February 2016 were identified. Records were then retrospectively reviewed to confirm APT use and to identify periprocedural complications. Antiplatelet agents evaluated included aspirin (low dose and full dose) and P2Y12 receptor antagonists (clopidogrel, prasugugrel, ticagrelor). Patients were excluded if they were taking a concurrent anticoagulant agent or if additional non-URS procedures were performed.
Results:
Of 4799 URS procedures, 314 (6.5%) were performed on patients taking APT, of which 234 (74.5%) held APT, 63 (20.1%) continued APT, and 17 (5.4%) continued dual APT. The mean age was 70.1 years, and the majority of patients (69.6%) underwent a stone procedure with a stone-free rate of 80.2%. The overall bleeding-related complication rate was 1.9%, whereas the significant bleeding-related event rate was 1.6% and this did not differ among the groups (p = 0.3). The power to detect a 3% difference in bleeding between the groups was 0.95.
Conclusions:
Continuing APT in patients on chronic therapy does not appear to pose an increased risk of bleeding-related complications. Our findings support the current AUA guidelines as they relate to APT.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Cardiac Catheterization I: Pre-Procedure Overview
Cardiac Catheterization IV: Nursing Management

